6533b85cfe1ef96bd12bd521
RESEARCH PRODUCT
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention
Rodolfo MauceriVittorio FuscoAlberto BedogniGiuseppina CampisiSipmo Onj BoardLorenzo Lo MuzioOlga Di FedeVera Panzarellasubject
Genetics and Molecular Biology (all)medicine.medical_specialtyBevacizumabImmunology and Microbiology (all)lcsh:MedicineAngiogenesis InhibitorsReview ArticleBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineQuality of lifeSettore MED/28 - Malattie OdontostomatologicheNeoplasmsOral and maxillofacial pathologyEpidemiologymedicineHumansIntensive care medicineAdverse effectBiochemistry Genetics and Molecular Biology (all)Bone Density Conservation AgentsDiphosphonatesGeneral Immunology and MicrobiologySunitinibbusiness.industrylcsh:R030206 dentistryGeneral Medicinemedicine.diseaseDenosumab030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugdescription
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients. Furthermore, even if its epidemiology and pathogenesis have still not been fully clarified, several risk factors related to MRONJ have been recognized in prevention protocols. Three main risk factors are as follows: (i) the type of ONJ-related medications: antiresorptive (e.g., Bisphosphonates, Denosumab) and antiangiogenic drugs (e.g., Bevacizumab, Sunitinib); (ii) the category of patient at MRONJ risk: cancer versus non-cancer patient; (iii) the typologies and timing of dental treatments (e.g., before, during, or after the drug administration). The aim of this paper is to describe the new paradigm by the Italian Society of Oral Pathology and Medicine (SIPMO) on preventive dental management in patients at risk of MRONJ, prior to and during/after the administration of the aforementioned ONJ-related drugs. In reducing the risk of MRONJ, dentists and oral hygienists are key figures in applying a correct protocol of primary prevention for pre-treatment and in-treatment patients. However, the necessity of a multidisciplinary standardized approach, with a sustained dialogue among specialists involved, should be always adopted in order to improve the efficacy of preventive strategies and to ameliorate the patient’s quality of life.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 |